Current status of hepatocellular carcinoma treatment in Japan: Practical use of sorafenib (Nexavar®)

Clinical Drug Investigation

Volumn 32, Issue SUPPL. 2, 2012, Pages 25-35

  Kokudo, Norihiro ^a   Nakajima, Junta ^b   Hatano, Etsuro ^c   Numata, Kazushi ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b Obihiro Kosei General Hospital   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADVANCED CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONSTIPATION; DIARRHEA; DISEASE EXACERBATION; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; JAPAN; LIVER CELL CARCINOMA; LIVER DISEASE; LYMPH NODE METASTASIS; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN REDNESS; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; JAPAN; LIVER NEOPLASMS; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; PYRIDINES; TIME FACTORS;

EID: 84864650212     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/1163023-S0-000000000-00000     Document Type: Review

References (11)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr [Accessed 2010 Nov]
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4): 378-90
3. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (1): 25-34
4. Bayer. Nexavar approved in Japan for the treatment of advanced liver cancer. [media release]. 2009 May 20 [online]. Available from URL: http://www.onyx-pharm.com/view.cfm/589/Nexavar-Approved-in-Japan-for-the- Treatmentof-Advanced-Liver-Cancer
5. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47 (14): 2117-27
6. Li X, Feng GS, Zheng CS, et al. Expression of plasmavascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10 (19): 2878-82 (Pubitemid 39303010)
7. Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103 (4): 914-21 (Pubitemid 351506379)
8. Kudo M, Kubo S, Takayasu K, et al. Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatology research : the official journal of the Japan Society of Hepatology 2010; 40 (7): 686-92
9. Kudo M, Izumi N, Kokudo N, et al. Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version. Dig Dis 2011; 29 (3): 339-64
10. Morimoto M, Numata K, Kondo M, et al. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma patients: a multicenter study of Kanagawa Liver Study Group. Kanzo 2010; 51 (8): 411-17
11. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69 (2): 223-40